BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Health Canada Has Not Found Conclusive Evidence That Mefloquine Can Cause Long-Lasting And Permanent Neurological And Psychiatric Adverse Events

  June 2, 2017

   · 

  3 min read
• BioMidwest

  Spectrum Pharma Highlights Three Abstracts Of Clinical Data At The 2017 ASCO Annual Meeting In Chicago, Illinois, June 2-6, 2017

  June 2, 2017

   · 

  3 min read
• Biotech Bay

  Genomic Health Presents Data Further Demonstrating Ability Of Oncotype DX Tests To Optimize Outcomes In Patients Across Cancer Types

  June 2, 2017

   · 

  10 min read
• Drug Development

  Bristol-Myers Squibb Release: Opdivo (Nivolumab) Data In Patients With Advanced Cervical, Vaginal And Vulvar Cancers From Phase I/II Checkmate -358 Presented At ASCO

  June 2, 2017

   · 

  1 min read
• BioMidwest

  Thermo Fisher Scientific Release: Newly Redesigned Panels Align With Most Recent Published Evidence To Drive Cancer Research

  June 2, 2017

   · 

  3 min read
• Genetown

  New Data From Kihdney Cohort Shows Improved Biochemical Outcomes And Broad Range Patient Suitability With More Frequent Hemodialysis Using The NxStage System One

  June 2, 2017

   · 

  5 min read
• Business

  Pascale Witz Joins Regulus Board Of Directors

  June 2, 2017

   · 

  4 min read
• FDA

  OxOnc Announces That Co-Development Partner Has Received Approval In Japan And Taiwan For Crizotinib (Xalkori) As A First-Line Treatment For Patients With ROS1-Positive Non-Small Cell Lung Cancer

  June 2, 2017

   · 

  2 min read
• Genetown

  NovaDigm Therapeutics Awarded $6 Million By U.S. Department Of Defense To Conduct A Phase IIa Staphylococcus Aureus Vaccine Trial

  June 2, 2017

   · 

  5 min read
• Drug Development

  Eight Presentations At ASM Microbe Include Late Breaker From Cempra’s Phase III Fusidic Acid Study And Solithromycin Data On Gonorrhea And Otitis Media

  June 2, 2017

   · 

  5 min read